High bleeding risk (HBR) is common among patients after percutaneous coronary intervention (PCI) and may in turn increase the likelihood of ischaemic/thrombotic events, a recent sub-analysis of MODEL U-SES study has found.
Researchers retrospectively assessed 1,695 patients who had taken part in the multicentre, open-label, prospective observation MODEL U-SES study. Of the participants, 840 were deemed to have HBR after PCI, while 855 were not. Outcomes included ischaemic/thrombotic events—including cardiovascular death, myocardial infarction, ischaemic stroke, and stent thrombosis—and bleeding events at 1 year.
At follow-up, 1,616 (95.3 percent) provided eligible data, in which the cumulative incidence of ischaemic/thrombotic events was found to be 1.8 percent (n=31). Bleeding occurred in 21 patients, yielding an incidence rate of 1.2 percent.
Kaplan-Meier curves showed that ischaemic/thrombotic events occurred significantly more frequently in HBR patients (3.3 percent vs 0.6 percent; log-rank p<0.001), corresponding to a significant inverse probability of treatment weighting (IPTW)-adjusted risk estimate (hazard ratio [HR], 0.16, 95 percent confidence interval [CI], 0.05–0.50).
In particular, ischaemic stroke was significantly elevated in the HBR group, which likely drove the overall association (1.5 percent vs 0.1 percent; p=0.003).
On the other hand, bleeding events was only marginally more frequent in the HBR group, yielding a risk estimate that was only numerical in significance (1.8 percent vs 0.9 percent; log-rank p=0.109; IPTW-adjusted HR, 0.46, 95 percent CI, 0.17–1.28).